These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 32577940)

  • 21. A single institution experience with palbociclib toxicity requiring dose modifications.
    Gong J; Cho M; Yu KW; Waisman J; Yuan Y; Mortimer J
    Breast Cancer Res Treat; 2018 Apr; 168(2):381-387. PubMed ID: 29218462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer.
    Yuan Y; Lee JS; Yost SE; Frankel PH; Ruel C; Egelston CA; Guo W; Padam S; Tang A; Martinez N; Schmolze D; Presant C; Ebrahimi B; Yeon C; Sedrak M; Patel N; Portnow J; Lee P; Mortimer J
    Eur J Cancer; 2021 Sep; 154():11-20. PubMed ID: 34217908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
    Mangini NS; Wesolowski R; Ramaswamy B; Lustberg MB; Berger MJ
    Ann Pharmacother; 2015 Nov; 49(11):1252-60. PubMed ID: 26324355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience.
    Battisti NML; Kingston B; King J; Denton A; Waters S; Sita-Lumsden A; Rehman F; Stavraka C; Kristeleit H; Sawyer E; Houghton D; Davidson N; Howell S; Choy J; Harper P; Roylance R; Fharat R; Mohammed K; Ring A; Johnston S
    Breast Cancer Res Treat; 2019 Apr; 174(3):731-740. PubMed ID: 30656459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
    Turner NC; Slamon DJ; Ro J; Bondarenko I; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Loibl S; André F; Puyana Theall K; Huang X; Giorgetti C; Huang Bartlett C; Cristofanilli M
    N Engl J Med; 2018 Nov; 379(20):1926-1936. PubMed ID: 30345905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
    Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
    Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
    Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
    BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.
    Stearns V; Brufsky AM; Verma S; Cotter MJ; Lu DR; Dequen F; Joy AA
    Clin Breast Cancer; 2018 Dec; 18(6):e1239-e1245. PubMed ID: 30172722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Patients treated with palbociclib and endocrine therapy for metastatic breast cancer: Can we predict the occurrence of severe early hematological toxicity?].
    Vazquez L; Arnaud A; Grenier J; Debourdeau P
    Bull Cancer; 2021 May; 108(5):544-552. PubMed ID: 33820647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Palbociclib and Fulvestrant in Japanese Patients With ER+/HER2- Advanced/Metastatic Breast Cancer.
    Seki H; Sakurai T; Maeda Y; Oki N; Aoyama M; Yamaguchi R; Tokuda T; Kaburagi T; Okumura T; Karahashi T; Nakajima K; Higeta K; Shimizu K
    In Vivo; 2019; 33(6):2037-2044. PubMed ID: 31662535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study.
    Im SA; Mukai H; Park IH; Masuda N; Shimizu C; Kim SB; Im YH; Ohtani S; Huang Bartlett C; Lu DR; Iyer S; Mori Y; Mori A; Gauthier E; Finn RS; Toi M
    J Glob Oncol; 2019 May; 5():1-19. PubMed ID: 31125276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
    Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
    Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
    Finn RS; Boer K; Bondarenko I; Patel R; Pinter T; Schmidt M; Shparyk YV; Thummala A; Voitko N; Bananis E; McRoy L; Wilner K; Huang X; Kim S; Slamon DJ; Ettl J
    Breast Cancer Res Treat; 2020 Sep; 183(2):419-428. PubMed ID: 32683565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3.
    Masuda N; Mukai H; Inoue K; Rai Y; Ohno S; Ohtani S; Shimizu C; Hashigaki S; Muramatsu Y; Umeyama Y; Iwata H; Toi M
    Breast Cancer; 2021 Mar; 28(2):335-345. PubMed ID: 33085032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Palbociclib in adults aged 70 years and older with advanced breast cancer: A phase 2 multicenter trial (Alliance A171601).
    Sedrak MS; Lee MK; Ji J; Satele DV; Freedman RA; Poorvu PD; O'Connor T; Williams GR; Hopkins JO; Muss HB; Cohen HJ; Partridge AH; Carey LA; Chow SL; Subbiah N; Le-Rademacher J; Jatoi A
    J Geriatr Oncol; 2024 Jul; 15(6):101813. PubMed ID: 38852379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
    DeMichele A; Clark AS; Tan KS; Heitjan DF; Gramlich K; Gallagher M; Lal P; Feldman M; Zhang P; Colameco C; Lewis D; Langer M; Goodman N; Domchek S; Gogineni K; Rosen M; Fox K; O'Dwyer P
    Clin Cancer Res; 2015 Mar; 21(5):995-1001. PubMed ID: 25501126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The safety and efficacy of palbociclib in the treatment of metastatic breast cancer.
    Ettl J; Harbeck N
    Expert Rev Anticancer Ther; 2017 Aug; 17(8):661-668. PubMed ID: 28649895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial.
    van Ommen-Nijhof A; Konings IR; van Zeijl CJJ; Uyl-de Groot CA; van der Noort V; Jager A; Sonke GS;
    BMC Cancer; 2018 Nov; 18(1):1146. PubMed ID: 30458732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
    Giuliano M; Schettini F; Rognoni C; Milani M; Jerusalem G; Bachelot T; De Laurentiis M; Thomas G; De Placido P; Arpino G; De Placido S; Cristofanilli M; Giordano A; Puglisi F; Pistilli B; Prat A; Del Mastro L; Venturini S; Generali D
    Lancet Oncol; 2019 Oct; 20(10):1360-1369. PubMed ID: 31494037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
    Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
    Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.